In patients with rheumatologic diseases, treatment with interleukin inhibitors may increase the risk of serious infections, opportunistic infections, and cancer, according to a systematic review and meta-analysis published in JAMA Network Open.
Researchers of the study aimed to determine the differences in muscle area and bone density in patients with end-stage lung disease.
Researchers aimed to develop a stratification method to evaluate symptom prevalence and distinct treatment responses in patients with Sjogren syndrome.
Polymicrobial prosthetic joint infections managed with surgical debridement, antibiotics and implant retention (DAIR) had high readmission rates and deep surgical site infections.
There is a substantial burden, unawareness, and undertreatment of several systemic comorbidities—particularly cardiovascular and psychiatric—in patients with HS.
The FDA has granted Breakthrough Therapy designation to nintedanib (Ofev; Boehringer Ingelheim) for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Low bone mineral density (BMD) is common in childhood leukemia and lymphoma survivors.
Researchers evaluated the outcomes of patients with immune checkpoint inhibitor-induced inflammatory arthritis and assessed the risk factors for long-term disease requiring immunomodulatory treatment.
Eight candidate touchpoints are associated with increased risk of fatal opioid overdose.
For patients with progressive fibrosing interstitial lung diseases, nintedanib is associated with a lower rate of decline in forced vital capacity (FVC) compared with placebo.
